Background The role of prostate-specific antigen (PSA) isoforms in the detection of prostate cancer in a non-screened population in the UK remains to be determined.
Introduction
Prostate cancer is now the second commonest cancer in men in the UK. Each year, there are approximately 22 000 new cases and approximately 9500 deaths attributable to the disease. 1 Since its introduction in the late 1980s, prostate-speci¢c antigen (PSA) remains the most widely used marker for the detection of prostate cancer. However, although PSA testing is associated with a high level of sensitivity using conventional cut-o¡ concentrations, the speci¢city of the test is low since patients with benign prostatic disease may also have elevated PSA concentrations.
A number of alternative approaches have been devised in an attempt to improve the speci¢city of the total PSA test, including the use of age-adjusted reference ranges, PSA density, PSA transitional zone density and PSA velocity. However, none of these derived values has gained widespread acceptance in routine clinical practice.
Recently, the discovery of di¡erent isoforms of PSA has generated further interest. Circulating PSA can be divided into two main forms: complexed and free. Most circulating PSA is bound to a variety of protease inhibitors, most commonly a-1-antichymotrypsin, and the proportion of the total PSA concentration which is free or unbound is relatively small. It has been suggested that, since the proportion of complexed PSA is greater in serum from patients with prostate cancer than in those with benign prostatic disease, measurements of complexed PSA would provide a more speci¢c test than total PSA. 2 Initially, there was no reliable method of measuring the complexed PSA concentration directly and it was therefore calculated by subtracting the unbound or
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`free' PSA concentration from the total PSA concentration. More recently, a method of directly measuring the concentration of complexed PSA has been developed. 3 Several studies have suggested that the use of these PSA isoforms or their ratios provides greater speci¢city than does total PSA in the detection of prostate cancer. 4^8 However, most of these studies were retrospective and based on asymptomatic, screened populations in North America. In contrast, in the UK, where there is no formal screening programme, more patients are symptomatic at presentation and the proportion of patients with prostate cancer is greater. The value of PSA isoforms and their ratios in a typical symptomatic, non-screened population in the UK has not been established.
The aim of the present study was to evaluate the role of PSA and its isoforms in the detection of prostate cancer in a non-screened population in the UK.
Patients and methods
Consecutive patients undergoing diagnostic transrectal ultrasound-guided (TRUS) biopsy of the prostate were studied prospectively. The indication for TRUS biopsy was either a total PSA concentration greater than 4 mg/L and/or an abnormal digital rectal examination. None of the patients had participated in a formal screening programme. All patients underwent a minimum of systematic sextant biopsy.
Prior to biopsy, a blood sample was obtained and the serum stored at^20 o C. No patients had undergone a digital rectal examination within a 2-week period prior to sampling and none were receiving treatment at the time of blood sampling.
Total and complexed PSA concentrations were measured using the Bayer ADVIA Centaur assay system (Bayer Plc, Bayer House, Newbury, UK). Total and free PSA concentrations were measured using the Immulite 2000 immunoassay system (Diagnostic Products Corporation UK, Glyn Rhonwy, Llanberis, UK). The inter-assay variabilities, as quoted by the manufacturer, were 56% and 53% for total and complexed PSA, respectively (Bayer assay system), with assay sensitivities of 0.01 and 0.03 mg/L, respectively. The inter-assay variabilities were 54% and 56% for total and free PSA, respectively (Immulite assay system), with assay sensitivities of 0.01 and 0.03 mg/ L, respectively.
The study was approved by the local ethics committee.
Statistical analysis
Data are presented as median and range. Where appropriate, comparison between unpaired data was carried out using the Mann^Whitney U-test. Agreement between the two methods of measuring total PSA was assessed using a paired sample Student's t-test. Correlations between two variables were calculated using Spearman's rank correlation test.
Receiver operating characteristics (ROC) curves were generated by plotting the sensitivity versus (1^speci¢city), as previously described. 9 The area under the ROC curve was calculated for total PSA, complexed PSA and free PSA concentrations, and for complexed-to-total and free-to-total PSA ratios. Analysis was performed using SPSS software (SPSS Inc, Chicago, Illinois, USA).
Results
One hundred and seventy-one men were included in the study. Of these, 103 (60%) were found to have histologically proven prostate cancer, eight (5%) had prostatic intra-epithelial neoplasia and the remaining 60 (35%) had benign prostatic disease. For the purpose of this study, patients with prostatic intraepithelial neoplasia were included in the non-cancer group. The median ages in the benign and cancer groups were 66 years (range 45^79) and 69 years (range 46^88, P50.01), respectively.
The results of the total, complexed and free PSA assays are shown in Table 1 .When the two methods of measuring total PSA were compared, the di¡erence between the values obtained using the two assays was shown to vary in proportion to the PSA concentration. Using a paired sample t-test, the values obtained using the Immulite 2000 assay were signi¢cantly higher, by a mean of 12.5% [95% con¢dence interval (CI) 10^15%, P50.001], than the values obtained using the Bayer assay.
There was a signi¢cant positive correlation between the values for total PSA concentration and those for complexed (rˆ0.978, P50.001) and free PSA (rˆ0.807, P50.001) concentrations. There was also a signi¢cant negative correlation between total PSA concentration and the free-to-total PSA ratio (rˆ70.346, P50.001).
Total PSA concentration, measured using both techniques, was signi¢cantly greater in the patients with histologically con¢rmed prostate cancer compared with patients with benign disease (P50.001; see Table 1 ). There were also signi¢cant di¡erences in the concentrations of complexed PSA (P50.001), complexed/total PSA (Pˆ0.033) and free/ total PSA (P50.001) between patients with prostate cancer and those with benign disease.
When all patients were examined, ROC analysis showed that the areas under the ROC curves for total and complexed PSA, and the free-to-total PSA ratio, were similar (see Fig. 1 , Table 1 ).
Using the conventional diagnostic cut-o¡ of 4 mg/L, as measured by the Bayer assay, the sensitivity and speci¢city of total PSA were 90% and 24%, respectively (see Table 2 ). Fixing the sensitivity of the other assays at 90%, the corresponding speci¢cities for complexed PSA and the free-to-total PSA ratio were 24% and 21%, respectively.
Seventy-seven patients had total PSA concentrations between 2 and 10 mg/L, as measured using the Bayer assay (see Table 3 ). ROC curve analysis showed that total and complexed PSA failed to discriminate between benign and malignant disease. In contrast, the areas under the curve were greater for the complexed-to-total PSA (Pˆ0.057) and the free-tototal PSA (Pˆ0.033) ratios (see Fig. 2 ). Using the conventional cut-o¡ of 4 mg/L, the speci-¢cities for the complexed-to-total and free-to-total ratios were 40% and 42%, respectively, compared with approximately 20% for both total and complexed PSA concentrations (see Table 4 ).
Discussion
The use of PSA to detect prostate cancer is well established. However, although PSA has been shown to be a highly sensitive method of detecting the presence of prostate cancer, concern has been expressed about the relative lack of speci¢city, particularly in screened populations, in which low speci¢city results in a high proportion of unnecessary biopsies. 4^8 As a result, there is increasing interest in the use of the complexed and free isoforms of PSA as a potential method of increasing the ability to discriminate between those Most of the information about free and complexed PSA has been derived from studies based on screened populations. For example, Bangma et al. 4 found that the free-to-total PSA ratio was more speci¢c than the total PSA concentration, but only in patients with a total PSA greater than 7 mg/L. Subsequently, Catalona et al. 5 reported that the use of the free-to-total PSA ratio increased speci¢city by 4^10 mg/L, while maintaining sensitivity. Brawer et al. 6 initially reported that complexed PSA performed better than did either total PSA concentration or the free-to-total PSA ratio. Brawer et al. subsequently reported that the speci¢city of complexed PSA concentration was equivalent to that of the free-to-total PSA ratio. 7 In contrast, Okihara et al. 8 reported that complexed PSA concentration was equivalent to total PSA concentration and that the free-to-total PSA ratio was superior to both. Some of these apparent contradictions might be explained by the retrospective nature of some of these studies, the use of non-consecutive subjects and the use of di¡erent total PSA concentrations to de¢ne the patient population of interest.
The clinical value of complexed and free PSA concentrations, and their ratios, especially for routine clinical practice in an unscreened population, remains uncertain. Some studies have failed to show an advantage in the use of the free-to-total PSA ratio compared with total PSA concentration; 10,11 however, the numbers studied were small. In contrast, Jung et al. 12 reported that, in patients with total PSA concentrations between 2 and 10 mg/L, complexed PSA concentration was equivalent to total PSA concentration, but that speci¢city increased substantially if one of the three PSA ratios (complexed-to-total, free-tototal or free-to-complexed) was used.
The results of the present study, in an unscreened population, show that, overall, there were signi¢cant di¡erences in the total and complexed PSA concentrations, in the complexed-to-total PSA ratios and in the free-to-total PSA ratios, in patients with prostate cancer compared with those with benign disease. Indeed, ROC curve analysis showed that the areas under the curves for total and complexed PSA concentrations and for the free-to-total PSA ratio were similar. Using the conventional cut-o¡ of 4 mg/L for total PSA concentration, the corresponding speci¢cities for total PSA concentration, complexed PSA concentration and the free-to-total PSA ratio were also similar.
Con¢ning the analysis to the 77 patients with total PSA concentrations between 2 and 10 mg/L, ROC curve analysis demonstrated that the complexed-tototal and the free-to-total PSA ratios were better than the total PSA concentration in discriminating between patients with benign and malignant disease. These results are therefore similar to those reported by Jung et al. 12 
Conclusion
Overall, the results of the present study, in a nonscreened population, show that the use of the PSA isoform concentrations and their ratios did not provide additional discriminatory power. However, in a subset of patients with total PSA concentrations between 2 and 10 mg/L, the free-to-total PSA ratio was superior to total PSA concentration in discriminating between patients with benign and malignant disease.
